Acral Melanoma Clinical Trial
Official title:
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05512481 -
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
|
Phase 2 | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Recruiting |
NCT04331093 -
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
|
Phase 2 | |
Not yet recruiting |
NCT05436990 -
Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
|
Phase 2 | |
Completed |
NCT00788775 -
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
|
Phase 2 | |
Recruiting |
NCT05086692 -
A Beta-only IL-2 ImmunoTherapY Study
|
Phase 1/Phase 2 |